Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • About Shruti
  • Books
  • Insights
  • Operational Excellence
  • Research
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
  • Case Studies
  • Tools
    • Whitepapers
    • Articles >
      • Business Transformation
      • Process Improvement
      • Business Continuity
      • Change Management
      • Digital Transformation
      • Quality Improvement
    • Checklists and Templates
    • Free eBook
    • Videos
  • Blog
  • Engage Shruti
    • Consulting >
      • Operational Excellence Consulting
      • Business Transformation Consulting
      • Innovation Management Consulting
    • Workshops
  • Contact

MUCOSAL DELIVERY OF PEPTIDE BASED THERAPEUTICS- The wave of future?

5/29/2009

0 Comments

 
Management of illness through medication has entered a new era in which an enormous number of biotechnology based products, peptides / proteins pharmaceuticals are available / synthesized for therapeutic use.  The growing interest can be ascribed to the increased understanding of their role in physiology and therapy as well as the established capability of producing large quantities with consistent quality by the biotech route. As technological innovation spreads throughout medicine so does the "cutting edge" come to drug delivery systems alias ‘Mucoadhesive Drug Delivery’.

Some examples of this system include, the BioErodible MucoAdhesive (BEMA) delivery system is designed to deliver either local or systemic levels of drugs across mucosal tissues. This delivery system offers rapid onset of action and improved drug bioavailability compared with the oral route. As an added benefit, drug inactivation by first-pass metabolism in the liver is avoided. The BEMA delivery system consists of a dime-sized disk with bioerodible layers that delivers drugs rapidly over specified time intervals. The erosion rate is controllable, and there is no residue to remove and so far has shown promise for the administration of pain medications, antiemetics, and antimigraine drugs (Clinical Trials, 2008, February). 

One example of this technology is the BEMA Fentanyl mouth patch from BioDelivery Sciences International (Raleigh, NC), which is currently in phase III trials. It is designed to assist with breakthrough cancer pain for opioid-tolerant patients. Dr. James North, MD, principal investigator for the phase III efficacy study reports, "Breakthrough cancer pain can be devastating to patients with cancer and their families. Patients suffering from breakthrough cancer pain need treatment options that provide effective pain relief and are easy to administer" (Triangle Business Journal, 2009, May) .  

Mucosal drug delivery technologies are expanding exponentially with applications in every imaginable route of administration because of the indisputable therapeutic benefit this delivery technology brings. Benefits include site-specific targeting, less frequent dosing, and maintaining effective plasma concentration without increased consumption.

The global market for advanced drug delivery systems was more than € 37.9 billion in 2000 and is estimated to grow and cross € 95 B  (i.e., controlled release €19.8B, needle-less injection € 0.8B, injectable /impantable polymer systems €5.4B, transdermal € 9.6B, transnasal €12.0B, pulmonary € 17.0B, transmucosal €4.9B, rectal €0.9B, liposomal drug delivery € 2.5B, cell/gene therapy € 3.8B, and balance covered by miscellaneous ).  

The objective of this series of review articles is to understand the opportunities available to delivery peptides and protein molecules as mucosal DDS and the complexities associated with the formulation thereof. 

The development of delivery systems for therapeutic peptides and proteins and their evaluation depend on the biophysical, biochemical and physiological characteristics of the peptide molecules including their molecular size, bio half-life, immunogenecity, conformational stability, dose requirement, site & rate of administration, pharmacokinetics and pharmacodynamics.  The immunogenic potential of any impurities or the peptide molecule itself must also be taken into consideration.  Since, peptides are complex structures and exhibit anomalous behavior (against conventional drug moieties) to environmental conditions; the study of its chemistry, preparation, purification etc. before dosage form design (since these parameters affect its stability on shelf) becomes vital. 

To begin with, in the next post, let us first understand the chemistry and the complexities of peptides and formulation considerations of peptide based therapies employing mucosal routes of administration.
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement
    To contact Dr. Shruti Bhat text or WhatsApp at 1.403.969.6219

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​Twitter, YouTube, LinkedIn​

© Copyright 1992- 2025 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media